HCP

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

Retrieved on: 
Tuesday, March 5, 2024
Software, Health, Diabetes, Medical Devices, Health Technology, Wearables, Mobile Technology, Technology, Clinical Trials, Tandem, HCP, CGM, Apple Watch, G6, Diabetic ketoacidosis, AID, DXCM, G7, Hypoglycemia, GLP1, Conference, Type 2 diabetes, ATTD, Type 2, Patient, Insulin, Apple, Mortality, Pharmaceutical industry

Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.

Key Points: 
  • Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.
  • Globally, we’ve expanded access to Dexcom products by over 5 million people,” said Kevin Sayer, President, CEO, and Chairman of the Board at Dexcom.
  • Dexcom has continued to drive access to its pioneering real-time CGM technology, launching its best-in-class G7 sensor in 16 new markets since ATTD 2023.
  • Further demonstrating the value of AID systems powered by Dexcom CGM, Dexcom will showcase recently published evidence at ATTD 2024.

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Fast Track, Therapy, HCP, Chronic liver disease, David Berry (inventor), Recurrence, Clostridioides difficile infection, Infection, Research, Fast track (FDA), Education, FDA, Term loan, Variometer, Growth, Use, Retirement, ID, Sale, CDI, Immunodeficiency, Oaktree Capital Management, Risk, Commercial, Graft-versus-host disease, Intensive care medicine, Medicare, Spore, Patient, Medicare Part D, Acceleration, Gastroenterology, Clostridioides, Limitation, AMR, Pharmaceutical industry

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2023 financial results and provided business updates.
  • From launch through year-end 2023, there were 2,833 completed prescription enrollment forms received for VOWST, of those 2,015 resulted in new patient starts by year-end 2023.
  • Strong adoption of VOWST since commercial launch in June 2023 with broad utilization, continued quarter over quarter growth, and significant progress achieving patient access.
  • General and administrative expenses for the fourth quarter of 2023 were $17.2 million, compared with $22.4 million for the same period in 2022.

Simplifying Health Insurance Data Analytics with Mark Farrah Associates’ Health Coverage Portal

Retrieved on: 
Thursday, February 29, 2024
Technology, Insurance, Finance, Banking, Professional Services, Health Insurance, Managed Care, Data Analytics, Health, Data Management, HCP, National Association, MFA, Parent, Loss, Small group, California Department, DMHC, Commercial, History, Medicare, Medicaid, NAIC, Communes of Burundi, FREE, Bank statement, Health insurance

Mark Farrah Associates (MFA) , a leading data aggregator and publisher of health plan market data and analytics, aggregates industry metrics from statutory financial statements filed with state insurance regulators in its Health Coverage Portal™ (HCP) database tool.

Key Points: 
  • Mark Farrah Associates (MFA) , a leading data aggregator and publisher of health plan market data and analytics, aggregates industry metrics from statutory financial statements filed with state insurance regulators in its Health Coverage Portal™ (HCP) database tool.
  • To further simplify the analysis of health insurance business, MFA presents its enhanced Health Coverage Portal™ to provide expanded capabilities and time-saving ease of use for the analysis of annual and quarterly enrollment, financials and industry ratios for health plans across the country.
  • For companies seeking comprehensive market data, MFA offers the Health Coverage Portal™ , an online application that integrates NAIC and CA DMHC financial statements, relevant government reports and MFA self-insured datasets.
  • To learn more about the Health Coverage Portal™ and MFA’s other valuable health insurance analytic tools, contact Mark Farrah Associates at 724-338-4100 or visit www.markfarrah.com .

CI&T Advances the Digital Health Ecosystem for Patients and Providers at HIMSS24

Retrieved on: 
Thursday, February 29, 2024
Health, Technology, Health Technology, Other Technology, Software, General Health, Artificial Intelligence, HCP, Digital Solutions, AI, SVP, HIMSS, Conference, Health care, Triage, Bayer, CI&T, Patient, Cieślak, Health system, Partnership

CI&T partners with some of the largest pharmaceutical, consumer healthcare and medical device companies in the world to help create innovative digital experiences for patients and healthcare professionals.

Key Points: 
  • CI&T partners with some of the largest pharmaceutical, consumer healthcare and medical device companies in the world to help create innovative digital experiences for patients and healthcare professionals.
  • From HCP Engagement and Digital Front Door solutions to Patient Triage through AI, CI&T offers clients unique cross-channel solutions for their challenges for the entire journey of patients, practitioners, and payors.
  • “ Can AI Fix the Health System ” will explore how AI can help orchestrate a seamless health ecosystem that elevates patient experience and drives improved outcomes.
  • Immersive Solution for HCP Training – An immersive AR experience for training doctors using digital twins, personalized training journeys and remote mentoring.

GoodRx Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, February 29, 2024
Health, Technology, Health Insurance, General Health, Internet, Pharmaceutical, GoodRx, HCP, Repurchase agreement, Share repurchase, Macs, Marketing, Gold, Adjustment, IPO, Interim, Advertising, GAAP, Partnership, Pharmaceutical industry

GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S., has released its financial results for the fourth quarter and full year 2023, which are consistent with its preliminary results announced on January 10, 2024.

Key Points: 
  • GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S., has released its financial results for the fourth quarter and full year 2023, which are consistent with its preliminary results announced on January 10, 2024.
  • Revenue excluding the $10.0 million client contract termination payment represents Adjusted Revenue for the third quarter and full year 2023.
  • Kroger Savings Club revenue was over $1 million less in the fourth quarter of 2023 than in the prior year period.
  • The prior year quarter included over $2 million of revenue related to vitaCare, whereas in the fourth quarter of 2023 there was essentially none.

Applied Biomics Launches Anti-Host Cell Protein (HCP) Antibodies with > 95% Coverage

Retrieved on: 
Thursday, February 29, 2024
Biotechnology, Science, Health, Research, HCP, LMW, HMW, WB, C6, ELISA, Proteomics, Antibody, HEK293, CHO, Map, CAP, Fine chemical

Applied Biomics, Inc. , a leading Proteomics service provider, launches a new product line offering Anti-HCP Antibodies with well over 95% coverage.

Key Points: 
  • Applied Biomics, Inc. , a leading Proteomics service provider, launches a new product line offering Anti-HCP Antibodies with well over 95% coverage.
  • View the full release here: https://www.businesswire.com/news/home/20240228749573/en/
    Antibody Coverage of Applied Biomics' Anti-CHO Antibody by 2D Western Blot (WB).
  • Following are highlights of Applied Biomics’ HCP Antibodies:
    High HCP coverage: Detects well over 2500 (up to ~5000) low and high molecular weight (LMW & HMW) HCPs, with > 95% overall HCP coverage and > 90% each quadrant coverage.
  • With our leading HCP antibody coverage services , customers can now test Applied Biomics’ HCP antibody against their process specific HCPs, or compare with other HCP antibodies to find a better fit.

Real Chemistry Announces 2023 Business Highlights

Retrieved on: 
Wednesday, February 28, 2024
Electronic Design Automation, Data Management, Technology, Other Communications, Pharmaceutical, Publishing, Public Relations, Investor Relations, Marketing, Communications, Social Media, Other Professional Services, Search Engine Optimization, Search Engine Marketing, Consulting, Artificial Intelligence, Science, Biotechnology, Professional Services, Health, Other Technology, Other Science, General Health, Real Chemistry, HCP, AI, Swoop, Investment, Real, Growth, TI, PRWeek, Chemistry, Synthetic media, Convergence of random variables, Creativity, Patient, RCIS, Diagnosis, Partnership, Medical device

“We achieved industry-leading growth despite a challenging year for our industry and our clients,” said Shankar Narayanan, CEO of Real Chemistry.

Key Points: 
  • “We achieved industry-leading growth despite a challenging year for our industry and our clients,” said Shankar Narayanan, CEO of Real Chemistry.
  • Our Swoop business achieved record growth in 2023, as precise targeting of healthcare providers and patients has become essential to pharmaceutical marketers.
  • Real Chemistry embedded innovation across the company and its business by making new generative AI tools available to all employees.
  • Real Chemistry entered a partnership with enterprise Generative AI expert Writer.ai , giving all Real Chemistry team members access to the Writer platform tool.

Reltio Introduces Groundbreaking AI-powered Capabilities that Strengthen Data Unification and Simplify the User Experience

Retrieved on: 
Wednesday, February 21, 2024
Professional Services, Data Management, Technology, Data Analytics, Software, Artificial Intelligence, HCP, UI, Senior, AI, Gen, RIA, Data management, FERN, Product management, LLM, Automation

The company’s expanded use of AI in the latest release is a critical milestone in its AI-first strategy for data unification and management.

Key Points: 
  • The company’s expanded use of AI in the latest release is a critical milestone in its AI-first strategy for data unification and management.
  • The Reltio Connected Data Platform™—the world’s leading data unification and management platform—powers generative AI (gen AI) and LLMs to strengthen data unification and accelerate time-to-value for core entity resolution and data stewardship tasks.
  • Key enhancements in the Reltio Connected Data Platform 2024.1 include the following:
    Reltio’s Flexible Entity Resolution Networks (FERN) for rule-free matching takes automation in data unification to the next level.
  • This helps free data stewards focus on handling critical issues that improve data accuracy and drive the curation of high-quality data.

Kadan Homecare Recognized as National Leader for Home Care

Retrieved on: 
Thursday, February 29, 2024
Employment, HCP, Caregiver, Communication, Nursing

ATLANTA, Feb. 29, 2024 /PRNewswire-PRWeb/ -- Kadan Homecare, a family-owned home care agency specializing in at-home care for seniors for more than three decades, announced today that it has been named a Leader in Experience, a Provider of Choice and an Employer of Choice as part of Home Care Pulse's 2024 Best of Home Care® recognition program. Home Care Pulse (HCP) promotes a high standard of care through the presentation of its annual awards. Through the program, home caregivers have true benchmarks to gauge their success, including satisfaction surveys, and access to continual online training.

Key Points: 
  • Home Care Pulse (HCP) promotes a high standard of care through the presentation of its annual awards.
  • "Our consistent recognition by Home Care Pulse as a leading homecare provider is a significant honor," said Dina Kadan White, President, Kadan Homecare.
  • As a Leader in Experience, Kadan Homecare is recognized among the top 10% of home care providers participating in the nationwide HCP Experience Management Program.
  • Kadan Homecare has worked extremely hard to prioritize high-quality care and employment, and their work hasn't gone unnoticed.

Petco Love's National Pet Vaccination Month in March Urges Pet Vaccinations to Save Pet Lives

Retrieved on: 
Thursday, February 29, 2024
Pet, SAN, HCP, Schering-Plough, Operation Kindness, DVM, Carnivore, Parvoviridae, Quality of life, Dog, Love, Parent, MBA, Food, Vaccine, Virus, Organization, Cat, Family, Disease, Partnership

SAN ANTONIO, Feb. 29, 2024 /PRNewswire/ -- During March's National Pet Vaccination Month, Petco Love, a national nonprofit organization, reminds pet parents of the importance of vaccinating their pets against deadly, yet preventable diseases in dogs and cats, at their veterinarian or local vaccine clinic. As part of its Vaccinated and Loved campaign and to support access to care for pets across the country, Petco Love is distributing pet vaccines to partner animal welfare organizations to hold free pet vaccine clinics in their communities.

Key Points: 
  • "No pet parent wants to see their pets suffer, especially from a disease that could have been prevented, and we know vaccines save pets lives."
  • Petco Love's Vaccinated and Loved campaign launched in 2021 to encourage Petco Love animal welfare partners to host free vaccine clinics.
  • Since that time, Petco Love distributed over 2.2M vaccines to date and surveyed pet parents1 attending these free clinics to assess their impact.
  • Pet parents in need of free pet vaccinations can visit care.petcolove.org to find a participating clinic.